Medifast Inc. reported a net loss of $3.1 million [3] for the second quarter of 2026, as revenue fell nearly 28 percent.
The results highlight the struggle of traditional weight-loss models to compete with the rise of GLP-1 medications. As consumers shift toward pharmaceutical interventions, Medifast faces a shrinking base of active earning coaches and declining sales of its core products.
Revenue for the second quarter reached $76.4 million [1], representing a 27.6 percent [2] decrease compared to the same period last year. The company reported a loss of 28 cents per share [4].
Based in Baltimore, Maryland, the company is currently executing a turnaround strategy. This plan centers on the rollout of the Trilivy brand, which is designed to pivot the company's metabolic health offerings to better align with current market demands.
Medifast is targeting a return to profitability in the fourth quarter of 2026. The company said the Trilivy rollout is a key component of this recovery path, though the transition remains risky as the active coach network continues to decline.
The company delivered these results via a webcast earnings call earlier this month. Management said productivity rose despite the sharp drop in overall revenue, attempting to stabilize the business while the new brand gains traction in the U.S. market.
“Revenue for the second quarter reached $76.4 million”
The steep revenue decline underscores a fundamental shift in the weight-loss industry. The popularity of GLP-1 drugs has disrupted the traditional 'coach-and-supplement' business model, forcing legacy companies like Medifast to either evolve their product lines or lose market share. The success of the Trilivy brand will determine if the company can successfully pivot to a metabolic health model that complements modern medical treatments.
